Article
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.
Journal of the European Academy of Dermatology and Venereology : JEADV - 1 Sept 2024
Muñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito M C, Sahuquillo-Torralba A, Baniandrés Rodríguez O, Herrera-Acosta E, Rivera-Diaz R, Ferran M, Sánchez-Carazo J L, Riera-Monroig J, Pujol-Montcusí J, Vidal D, de la Cueva P, García-Bustinduy M, Ruiz-Villaverde R, Ballescà F, Llamas-Velasco M, Navares M, Palomar-Moreno I, Sánchez-García I, García-Martínez J, Novalbos J, Zubiaur P, Abad-Santos F, Daudén-Tello E, de la Fuente H
Abstract excerpt
BACKGROUND: Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation. OBJECTIVE: To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting. METHODS: We studied 180 SNPs in patients with moderate-to-severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.